Last updated: 11/04/2018 11:34:24
A Clinical Evaluation Of BW430C (lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder– Long-term extension study (extension of study SCA104779 (NCT00550407))
Trial description: This study is planned to assess the long-term safety of lamotrigine in Japanese patients with bipolar I disorder who will continue into the 52-week extension upon completion of a double-blind comparative study (Study No.: SCA104779 (NCT00550407)), i.e. the patients who receive the addition of any additional treatment to intervene in a mood episode in the double-blind phase or the patients completing the double-blind phase.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Number of participants with any serious adverse event (SAE) and any non serious adverse event
Timeframe: From baseline (Week 0) until 2 weeks after the end of treatment (Week 54)
Number of participants with the indicated clinical laboratory test values for alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), gamma glutamyl transferase (GGT), and lactate dehydrogenase (LDH)
Timeframe: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/Early Withdrawal (EW)
Number of participants with clinical laboratory test values out of the normal range and in the normal range for total bilirubin and creatinine at Weeks 0, 6, 16, 28, 40, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of participants with clinical laboratory test values out of the normal range and in the normal range for calcium, cholesterol, chloride, potassium, sodium, triglycerides, and urea/blood urea nitrogen (BUN) at Weeks 0, 6, 16, 28, 40, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of participants with clinical laboratory test values out of the normal range and in the normal range for platelet count and white blood cell count at Weeks 0, 6, 16, 28, 40, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of participants with clinical laboratory test values out of the normal range and in the normal range for total protein, hemoglobin, and hematocrit at Weeks 0, 6, 16, 28, 40, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of participants with clinical laboratory test values out of the normal range and in the normal range for red blood cell count at Weeks 0, 6, 16, 28, 40, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of participants in the indicated category for urine glucose, urine protein, and urine urobilinogen at Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Mean systolic blood pressure and diastolic blood pressure of participants at Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Mean heart rate of participants at Week 0 (Baseline) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Mean weight of participants at Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Mean body mass index (BMI) of all participants at Week 0 (Baseline) and Weeks 6, 8, 12, 16, 20, 24, 28, 32,36, 40, 44, 48, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 0, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Number of participants with the indicated electrocardiogram (ECG) findings at Weeks 0, 6, 28, and 52/EW
Timeframe: Weeks 0, 6, 28, and 52/EW
Secondary outcomes:
Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Timeframe: Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Change from baseline in the Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW
Timeframe: Weeks 6, 16, 28, 40, and 52/EW
Change from baseline in the Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW
Timeframe: Weeks 6, 16, 28, 40, and 52/EW
Change from baseline in the Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW
Timeframe: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Median serum lamotrigine 200 mg concentration among participants with concomitant use of inducer and without inhibitor (at the timing of blood sample collection)
Timeframe: from Week 6 to Week 52/EW
Median serum lamotrigine 100 mg and 200 mg concentration among participants with concomitant use of inhibitor (at the timing of blood sample collection)
Timeframe: from Week 6 to Week 52/EW
Median serum lamotrigine 25, 100, 125, 150, 200, 225, 300, and 400 mg concentrations among participants without concomitant use of inhibitor and inducer
Timeframe: from Week 6 to Week 52/EW
Interventions:
Enrollment:
92
Primary completion date:
2010-20-10
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Tsukasa Koyama, Teruhiko Higuchi, Shigeto Yamawaki, Shigenobu Kanba, Takeshi Terao and Atsuko Shinohara. Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder – Long-term extension study –. Rinsho seishin igaku. 2011;40(7):981-995.
Medical condition
Bipolar Disorder
Product
lamotrigine
Collaborators
Not applicable
Study date(s)
May 2008 to October 2010
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
20+ years
Accepts healthy volunteers
No
- Of subjects participating in the preceding double-blind study, those who are judged by the investigator/sub-investigator to have well tolerated the double-blind treatment and to be eligible for the 52-week extension treatment
- Sex: either sex. Female of child-bearing potential will be eligible for inclusion in this study. However they have to have a negative pregnancy test at the start of this study, agree to further pregnancy testing at the time points determined in study assessments and procedures and practice one of the following methods of contraception from the start of this study until the end of the follow-up examination:
- Has a score of 3 or more on item of the HAM-D related to suicide or is at a high suicidal risk in the judgment of the investigator/sub-investigator
- Has a history of severe rash or rash due to anti-epileptic drugs
Inclusion and exclusion criteria
Inclusion criteria:
- Of subjects participating in the preceding double-blind study, those who are judged by the investigator/sub-investigator to have well tolerated the double-blind treatment and to be eligible for the 52-week extension treatment
- Sex: either sex. Female of child-bearing potential will be eligible for inclusion in this study. However they have to have a negative pregnancy test at the start of this study, agree to further pregnancy testing at the time points determined in study assessments and procedures and practice one of the following methods of contraception from the start of this study until the end of the follow-up examination: Abstinence Oral contraceptive, either combined or progestogen alone (except during the Dosage Adjustment Phase) Injectable progestogen Implants of levonorgestrel Estrogenic vaginal ring (except during the Dosage Adjustment Phase) Percutaneous contraceptive patches (except during the Dosage Adjustment Phase) Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject Double barrier method: condom or occlusive cap (diaphragm or cervical / vault caps) plus spermicidal agent (foam / gel / film / cream / suppository)
- In/Out patient: Either
- Informed consent: the subject capable of giving written informed consent
Exclusion criteria:
- Has a score of 3 or more on item of the HAM-D related to suicide or is at a high suicidal risk in the judgment of the investigator/sub-investigator
- Has a history of severe rash or rash due to anti-epileptic drugs
- Patients with severe hepatic/renal/cardiac/pulmonary disorder or hematopoietic disorder. The severity refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences" (PAB/SD Notification No. 80, dated 29 June 1992)
- Patients have less than 5 years of remission history from clinically significant malignancy (other than e.g. basal cell or squamous cell skin cancer, in-situ carcinoma of cervix or prostate CA in situ)
- Patients with chronic hepatitis typeB and /or typeC which is positive of hepatitis B surface antigen （HBsAg）and/or hepatitis C antibody
- Has an acute or chronic illness likely to impair drug absorption, distribution, metabolism or excretion or has any unstable physical symptoms likely to require hospitalisation during participation in the study
- Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study
- Has a history or current diagnosis of epilepsy
- Has received an investigational drug within 30 days of screening
- Patients with a history of drug allergy to any ingredient of the test-drug
- Patients whom the investigator or sub-investigator considers ineligible for the study
Trial location(s)
Showing 1 - 6 of 52 Results
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2010-20-10
Actual study completion date
2010-20-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website